title: Acute intravenous infusion of an adenosine regulating agent improves left ventricular function in dogs with advanced heart failure.
abstract: OBJECTIVE
  GP531 is a second generation adenosine regulating agent (ARA) that increases concentrations of endogenous adenosine, a natural cardioprotective agent, in ischemic/hypoxic tissue. This study examined the effects of acute intravenous infusions of GP531 on left ventricular (LV) systolic and diastolic function in dogs with advanced chronic heart failure (HF) (LV ejection fraction, EF <30 %).
  
  
  METHODS
  Six dogs with intracoronary microembolization-induced HF received a constant intravenous infusion of GP531 (10 μg/kg/min) or vehicle (normal saline) for 6 h in random order 1 week apart. Hemodynamic measurements were made at baseline and at 1, 2, 3, 4, 5 and 6 h after initiating drug infusion. Myocardial oxygen consumption (MVO2) was measured at baseline and 4 and 6 h. LV pressure-volume relationship (PVR) was measured at baseline and 6 h.
  
  
  RESULTS
  Vehicle infusions had no effect on indexes of LV systolic and diastolic function. GP531 infusion had no effect on heart rate or mean aortic pressure but significantly decreased LV end-diastolic pressure, end-diastolic volume, end-systolic volume and end-diastolic wall stress. GP531 significantly increased LV EF (27 ± 1 at baseline to 34 ± 1 after 6 h of drug infusion, p < 0.05), deceleration time of early mitral inflow velocity and the slope of end-systolic PVR without increasing MVO2.
  
  
  CONCLUSIONS
  Results of the study indicate that approaches which increase the local release of adenosine in failing LV myocardium, such as ARAs, have a favorable impact on LV performance. These observations support the continued development of ARA's for the treatment of acute HF syndromes.
authors.affiliation: Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI, 48202, USA.
authors.forename: Mengjun
authors.initials: M
authors.lastname: Wang
authors.forename: Ramesh C
authors.initials: RC
authors.lastname: Gupta
authors.forename: Sharad
authors.initials: S
authors.lastname: Rastogi
authors.forename: Smita
authors.initials: S
authors.lastname: Kohli
authors.forename: Kefei
authors.initials: K
authors.lastname: Zhang
authors.forename: David E
authors.initials: DE
authors.lastname: Lanfear
authors.forename: Hani N
authors.initials: HN
authors.lastname: Sabbah
mesh_terms: D000241:Adenosine / Q000502:physiology*; D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D003853:Deoxyribonucleosides / Q000494:pharmacology / Q000627:therapeutic use*; D004285:Dogs; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D007262:Infusions, Intravenous; D058915:Purinergic P1 Receptor Antagonists / Q000494:pharmacology; D013806:Theophylline / Q000031:analogs & derivatives / Q000494:pharmacology; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D003853:Deoxyribonucleosides; D058915:Purinergic P1 Receptor Antagonists; C103214:GP 531; D000620:Aminoimidazole Carboxamide; C031433:8-(4-sulfophenyl)theophylline; D013806:Theophylline; D000241:Adenosine